Decision based on data involving use of SpaceOAR® hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer. BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical ...
Prediction of significant prostate cancer in equivocal MRI lesions: A high-volume international multicenter study. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers Symposium.
TORONTO--(BUSINESS WIRE)--Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results